Article · 13 Feb 2026
Conference abstractPublished 8 Sep 2014
Clinical trial agreements: Important or just one more study document?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
A review of the current literature suggests that the clinical trial agreement (CTA) may be a problematic area for clinical trial investigators. Some experts in the field believe this document is critical to investigator conduct, yet it is one of the least understood study documents, rarely reviewed by investigators, and is often signed without reviewing the content. This key document governs the investigator?s conduct of the study, as does the protocol, investigator brochure, and informed consent. While experts claim this is a problematic area rife for potential conflict between sponsor and investigator that could have serious legal ramifications little or no scientific data to support this belief was found in the literature reviewed. Using social and behavioral methodologies, a survey was constructed to collect data on the factors influence investigators? knowledge, attitudes and perceptions about the CTA. Questions were framed to include all spheres of the Social Ecological Model and to analyze perceptions, beliefs and knowledge as outlined in the Health Belief Model. Surveys were sent to investigators throughout the US, in various clinical trial environments, regions, and organization type. The data collected will help to establish current practices and provide guidance for possible future interventions and additional research. This will be the first public presentation of the data collected to truly determine whether this is a problematic area and if so how severe is the problem.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “JoAnn P Pfeiffer”

